Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Veldoreotide-Quantum Dots for Breast Cancer
NCT04138342Phase 1Unknown
- Sponsor
- Al-Azhar University
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1 trial of veldoreotide in breast cancer (2 arms), sponsored by Al-Azhar University. Primary endpoints: Growth inhibition measured using the sulforhodamine B-based assay at 6 months, Amount of QDs-VELD fluorescent QDs-VELD in the breast periphery at 6 months and 1 more. Status: unknown.
02
Drugs
veldoreotide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04138342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138342.